Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis
Despite the enormous morbidity attributed to schistosomiasis, there is still no vaccine to combat the disease for the hundreds of millions of infected people. The anthelmintic drug, praziquantel, is the mainstay treatment option, although its molecular mechanism of action remains poorly defined. Pra...
Main Authors: | Mark S. Pearson, Bemnet A. Tedla, Luke Becker, Rie Nakajima, Al Jasinskas, Takafira Mduluza, Francisca Mutapi, Claude Oeuvray, Beatrice Greco, Javier Sotillo, Philip L. Felgner, Alex Loukas |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.663041/full |
Similar Items
-
Putting the treatment of paediatric schistosomiasis into context
by: Takafira Mduluza, et al.
Published: (2017-04-01) -
Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity
by: Tawanda J. Chisango, et al.
Published: (2019-03-01) -
Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children
by: Welcome M. Wami, et al.
Published: (2016-01-01) -
Immunomics in Pediatric Rheumatic Diseases
by: Shi Huan Tay, et al.
Published: (2019-05-01) -
Systemic Sclerosis Perturbs the Architecture of the Immunome
by: Bhairav Paleja, et al.
Published: (2020-08-01)